Published in
Clinical oncohematology, 3(10), p. 294-316, 2017
DOI: 10.21320/2500-2139-2017-10-3-294-316
Links
Tools
Group of Authors Under the Supervision of Academician Vg Savchenko
Journal article published in 2017 by
A. G. Turkina 
,
A. Y.-U. Zaritskii,
V. A. Shuvaev,
E. Y.-U. Chelysheva ,
E. G. Lomaia ,
E. V. Morozova,
A. K. Golenkov,
T. I. Pospelova,
O. A. Shukhov ,
M. S. Fominykh ,
G. A. Gusarova,
L. A. Kuz'mina ,
A. O. Abdullaev ,
I. S. Martynkevich
,
A. Y.-U. Zaritskii,
V. A. Shuvaev,
E. Y.-U. Chelysheva ,
E. G. Lomaia ,
E. V. Morozova,
A. K. Golenkov,
T. I. Pospelova,
O. A. Shukhov ,
M. S. Fominykh ,
G. A. Gusarova,
L. A. Kuz'mina ,
A. O. Abdullaev ,
I. S. Martynkevich
Abstract
This article is the 4th edition of the recommendations for the diagnosis and treatment of chronic myeloid leukemia. The group of authors reviewed and discussed relevant new publications, and included the significant remarks and comments of experts. Particular attention was paid to the control of risk factors for the development of arterial vascular events and their prevention, and adverse effects of the longterm therapy with tyrosine kinase inhibitors, which were being increasingly reported in recent years.